Drug Approval | August 06, 2023
Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
The product is being launched in August 2023
The product is being launched in August 2023
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Establishes distribution center in top hub for international shipping
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
